Replies to post #3325 on Insmed Inc (INSM)

[Do DD]

Well informed post from Yahoo.

SIGNIFICANT VALUE..

"BP3(important protein) showing efficacy 'in vivo' in LUNG COLON PROSTATE HEAD NECK & BREAST cancer tumor models.. by itself BP3 inhibits tumor growth TOTALLY in these models. In combination with standard therapuetic agents it's very synergistic. Looking forward to moving to PII study...GRANT already has been awarded from DOD to the BREAST CANCER Center of Excellence for refractory breast cancer."

"INS-18(small molecule) PII clinical data on refractory PROSTATE CANCER will be released before the end of this year.
Going to larger PII program for PROSTATE CANCER soon..."

Philip J. Young CBO - Rodman & Renshaw 8th Annual Healthcare Conference

[Christiaan F]

Young answered that progress on all stides will be touched upon in January 2007; he did not mention PhII results MMD.

Why would that be bashing? It's clear that during the trial process, INSM will not stress IPLEX and it's use for IGFD-market.

Just the non-hazardous zone; other indications.

CF